Orchestra BioMed Holdings (OBIO) Net Cash Flow Growth (3y) (2024 - 2026)

Orchestra BioMed Holdings (OBIO) Net Cash Flow Growth (3y) (2024 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) NCF Growth (3y) (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -50.33%
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 38.47%
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 33.37%
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -29.82%
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Orchestra BioMed Holdings 228.31 Mn 143.68 Mn 78,000.00 -79.73%

Historic Data

Download Data
DateValue
Mar 31, 2026 -79.73%
Dec 31, 2025 54.40%
Sep 30, 2025 63.01%
Jun 30, 2025 -82.71%
Mar 31, 2025 -30.09%
Dec 31, 2024 -387.66%
Sep 30, 2024 156.01%
Jun 30, 2024 128.55%
Mar 31, 2024 -355.86%